--- canonical_name: GHK-Cu alternate_names: copper tripeptide-1, GHK copper, glycyl-L-histidyl-L-lysine-Cu, copper peptide GHK-Cu, Cu-GHK canonical_topic: GHK-Cu for Health & Longevity short_topic_lc: ghk_cu creation_date: 2026-0811-0028 creator_ai_fullname: Grok 4 --- # GHK-Cu for Health & Longevity

Evidence Review created on 08/11/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4 **Also known as:** copper tripeptide-1, GHK copper, glycyl-L-histidyl-L-lysine-Cu, copper peptide GHK-Cu, Cu-GHK ## Motivation GHK-Cu is a small, naturally occurring copper-bound peptide found in human plasma, saliva, and urine. Interest in it for health and longevity stems from its reported roles in tissue repair, collagen support, and gene-expression shifts toward repair — and from the observation that circulating levels fall substantially between young adulthood and later life, in parallel with slower healing and matrix decline. Skin creams and wound-care studies form most of the human clinical base, with small controlled cosmetic trials and older ulcer pilots providing the main outcome data. Injectable whole-body use for longevity is common in peptide clinics and gray-market channels, but peer-reviewed human trials for those systemic routes remain sparse relative to marketing claims. This review examines the evidence for and against GHK-Cu as a health and longevity intervention: mechanisms, expected benefits and risks, practical protocols, sourcing quality, and monitoring — with emphasis on what is supported by controlled human data versus what remains early-stage lab work or clinic anecdote. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews that discuss GHK-Cu or copper-peptide regenerative biology in depth. - [Peptides: The Science, Uses & Safety – Dr. Abud Bakri](https://www.hubermanlab.com/episode/peptides-the-science-uses-and-safety-abud-bakri) - Andrew Huberman & Abud Bakri Clinical-practice-oriented discussion of GHK-Cu among research peptides, covering collagen, topical use, red light combinations, and sourcing caveats. - [#387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field](https://peterattiamd.com/ama83/) - Peter Attia Framework for judging gray-market injectable peptides by mechanism, human evidence, and sourcing risk — the same evaluation lens that applies to systemic GHK-Cu copper-delivery and tissue-repair claims. - [Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data](https://pubmed.ncbi.nlm.nih.gov/29986520/) - Pickart & Margolina, 2018 Comprehensive narrative review of skin, wound, gene-expression, and protective actions; primary literature map from a central research group (commercial interest noted). - [The potential of GHK as an anti-aging peptide](https://pubmed.ncbi.nlm.nih.gov/35083444/) - Dou et al., 2020 Concise academic overview linking age-related GHK decline to tissue remodeling, antioxidant, and early cognitive-animal data. No substantial dedicated GHK-Cu content was found from Rhonda Patrick (FoundMyFitness), Chris Kresser, or Lifespan.io as of the search date; brief or off-topic mentions were not treated as high-level overviews. Life Extension Magazine pieces that only mention copper peptide among many cosmetic ingredients without substantial GHK-Cu discussion were also excluded. Four high-level sources met inclusion criteria; the list was not padded with marginal content. ## Grokipedia - [Copper peptide GHK-Cu](https://grokipedia.com/page/Copper_peptide_GHK-Cu) Structured encyclopedia entry covering natural occurrence, age-related decline, regenerative mechanisms, cosmetic use, and emerging applications. ## Examine No Examine.com article for GHK-Cu was found. ## ConsumerLab No ConsumerLab review for GHK-Cu was found. ## Systematic Reviews No systematic reviews or meta-analyses for GHK-Cu were found on PubMed as of 11 August 2026. ## Mechanism of Action GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK). GHK binds copper with high affinity and acts as a physiological copper carrier, delivering Cu²⁺ to repair cells while limiting free copper redox damage. Primary actions center on extracellular matrix remodeling. In fibroblasts, GHK-Cu increases synthesis of collagen, elastin, and glycosaminoglycans (large sugar-protein matrix molecules that hold water and structure), while modulating matrix metalloproteinases (enzymes that break down matrix) and their inhibitors so remodeling can proceed without uncontrolled degradation. It supports angiogenesis (new blood vessel growth) and nerve outgrowth, attracts repair cells to injury sites, and reduces pro-inflammatory cytokines such as TNF-α (a key inflammation-signaling molecule) while supporting antioxidant enzymes. Gene-expression studies report broad shifts of thousands of transcripts toward repair and away from inflammatory and fibrosis programs — including suppression of NF-κB (a central inflammatory signaling hub). Copper is required for enzymes such as lysyl oxidase (cross-links collagen and elastin) and superoxide dismutase, linking copper delivery to structural and antioxidant function. GHK is a small water-soluble peptide (free GHK ≈ 340 Da; copper complex ≈ 404 Da). Selectivity is multi-target rather than single-receptor: effects span copper delivery, matrix remodeling, and broad gene shifts. Tissue exposure is highest at the application site; systemic distribution after injection is poorly mapped. Topical absorption needs carriers (nano-lipid, liposomal). Free-peptide plasma half-life is short (minutes to low hours); copper rides albumin and ceruloplasmin pathways. Metabolism is proteolytic, not cytochrome-P450 dependent. Injectable pharmacokinetics remain sparsely characterized. ## Historical Context & Evolution Loren Pickart isolated GHK in 1973 from human plasma albumin as a factor that restored more youthful protein synthesis patterns in aged liver tissue. Recognition that GHK tightly binds copper led to study of GHK-Cu as the bioactive complex. Early work focused on wound healing and tissue remodeling: chemoattraction of macrophages and endothelial cells, faster wound contraction, and improved tensile strength in animal models. By the 1980s–1990s, topical GHK-Cu entered clinical wound care (including diabetic ulcer pilots) and cosmetic “copper peptide” creams. Controlled facial studies reported improvements in skin density, fine lines, and firmness over 8–12 weeks. Pickart and collaborators later published gene-array analyses arguing that GHK resets large gene networks relevant to aging and disease. Much of the foundational literature originates from or cites this research group, which has commercial ties to copper-peptide skincare (Skin Biology) — a conflict of interest that should be weighed when interpreting narrative reviews. Longevity interest grew as plasma GHK levels were reported to fall from roughly 200 ng/mL around age 20 to about 80 ng/mL by age 60, parallel to slower healing and matrix decline. Compounding pharmacies and research-chemical vendors expanded injectable use for skin, hair, and “systemic regeneration,” outpacing large independent randomized controlled trials (RCTs). As of 2026, topical cosmetic use remains the best-studied human application; systemic longevity claims rest mainly on mechanism, animal data, and clinical anecdote. ## Expected Benefits ### Medium 🟩 🟩 #### Improved facial skin firmness, density, and fine lines Small controlled cosmetic trials of topical GHK-Cu (including nano-carrier formulations) report reduced wrinkle volume and depth and improved density and firmness over 8–12 weeks in middle-aged women with photoaging. One double-blind trial summarized in [Pickart & Margolina, 2018](https://pubmed.ncbi.nlm.nih.gov/29986520/) (n = 40) found about 56% relative reduction in wrinkle volume and 33% in depth versus control serum, and greater volume reduction than a Matrixyl 3000 comparator. Earlier industry-linked facial cream studies reported similar gains in laxity, clarity, and fine lines. Samples are modest and often commercially tied. **Magnitude:** ~32–56% relative reductions in wrinkle volume/depth vs vehicle or comparator in small 8-week trials; firmness/density improvements reported over 12 weeks. #### Accelerated cutaneous wound healing Topical GHK-Cu has been tested in diabetic and other ulcer settings and in acute wound models. Older controlled clinical work (e.g., the multicenter diabetic neuropathic ulcer gel trial by [Mulder et al., 1994](https://pubmed.ncbi.nlm.nih.gov/17147644/)) reported faster closure and higher complete-healing rates versus vehicle plus standard care in small cohorts. Animal and ex vivo data consistently show faster re-epithelialization and stronger matrix deposition. Human trials are limited in size and era; large modern multicenter RCTs are sparse, with new Phase 2 topical work underway. **Magnitude:** Faster closure reported in small diabetic-ulcer pilots (e.g., multi-fold faster rates or higher percent healed vs control in older studies); exact modern effect sizes vary by formulation and wound type. ### Low 🟩 #### Support for hair follicle environment and density Mechanistic and limited clinical/observational reports suggest GHK-Cu may enlarge follicle size, improve scalp microcirculation, and reduce local inflammation — pathways relevant to thinning hair. Controlled, large hair-growth RCTs with standardized endpoints (e.g., terminal hair count) remain limited relative to minoxidil or finasteride. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Collagen IV and dermal–epidermal junction support (with hyaluronic acid) Cell and ex vivo tests report strong collagen IV upregulation with GHK-Cu plus hyaluronic acid at optimized ratios. Human junction-specific clinical outcomes are not established; basis is laboratory only. #### Systemic regenerative and longevity gene-expression effects Gene-array analyses associate GHK with large expression shifts toward repair. Injectable longevity use is common in clinics, but human RCTs for healthspan or multi-organ outcomes are absent; the basis is mechanistic and anecdotal. #### Neuroprotection and cognitive resilience Reviews propose antioxidant, copper-homeostasis, and anti-inflammatory actions relevant to age-related cognitive decline. Early mouse observations of partial cognitive rescue exist. No adequate human cognitive trials of GHK-Cu were identified. #### Lung protection and anti-fibrotic effects Animal models of silicosis (silica-dust lung scarring), bleomycin fibrosis, and smoke injury show less inflammation and fibrosis and SIRT1-linked muscle recovery (SIRT1 is a longevity-linked enzyme helping cells handle stress). Human trials are lacking. ## Benefit-Modifying Factors - **Age-related GHK decline:** Circulating GHK falls roughly 60% from young adulthood to age ~60; older adults may have lower endogenous tone and theoretically more room to respond, though this is not proven in dose–response trials. - **Baseline skin and wound status:** Photoaged, lax, or chronically inflamed skin and stalled wounds are the populations studied clinically; pristine young skin yields smaller visible cosmetic deltas. - **Delivery system:** Nano-lipid, liposomal, and microneedle-assisted topicals improve dermal delivery versus simple aqueous solutions; poor vehicles underperform. - **Sex:** Most cosmetic RCTs enrolled women; sex-specific efficacy differences are not well defined. - **Copper status:** Severe copper deficiency or overload could alter response; typical topical doses add little systemic copper relative to diet. - **Concurrent matrix support:** Co-use with hyaluronic acid or sound protein intake may support collagen-related endpoints; smoking and uncontrolled hyperglycemia blunt wound and matrix outcomes. ## Potential Risks & Side Effects ### Medium 🟥 🟥 #### Product quality and contamination risk (injectable / research-grade) Injectable GHK-Cu sold as “research only” or via loosely regulated channels can contain incorrect dose, residual solvents, endotoxin, or wrong identity. Gray-market peptide risk is a dominant practical hazard for systemic use, independent of the molecule’s intrinsic toxicity profile. **Magnitude:** Not quantified in available studies. ### Low 🟥 #### Local irritation, stinging, injection-site reactions, or contact sensitivity Topical GHK-Cu can cause transient redness, itching, or stinging, especially at higher concentrations, on broken skin, or when used concurrently with strong acids or retinoids. Injectable use may cause injection-site redness, swelling, or local discomfort. True allergic contact dermatitis is uncommon but reported in sensitive users. **Magnitude:** Usually mild and self-limited with product adjustment; literature reports no incidence figure. #### Transient skin dullness or breakouts with overuse Some users report short-term duller appearance or breakouts when starting high-frequency copper peptides, often linked to remodeling imbalance or concurrent overuse of multiple actives. Controlled incidence data are sparse. **Magnitude:** Usually mild and reversible with reduced frequency or simplified routines; literature reports no incidence figure. #### Transient blue-green discoloration of skin or fabrics Copper complexes can tint skin or pillowcases at higher topical strengths or with residue. The effect is cosmetic rather than toxic in typical use and usually clears with product adjustment or cleansing. **Magnitude:** Cosmetic and self-limited with cleansing or product adjustment; literature reports no incidence figure. ### Speculative 🟨 #### Systemic copper excess with aggressive parenteral use High-dose injectable GHK-Cu plus copper supplements or poor copper excretion (e.g., Wilson disease, an inherited copper-overload disorder) is a theoretical risk. Standard topical use is unlikely to cause toxicity; peer-reviewed copper-toxicity cases are absent. #### Unknown long-term systemic safety of chronic injection Multi-year human safety databases for daily subcutaneous GHK-Cu do not exist at pharmaceutical scale. Mechanistic gene modulation is often framed as beneficial; off-target chronic effects remain uncharted. ## Risk-Modifying Factors - **Route of administration:** Topical cosmetic use has a longer safety track record; injectable use carries higher quality and systemic-unknown risk. - **Concentration and vehicle:** Higher percent creams and alcohol-heavy vehicles raise irritation; nano-carriers can increase delivery and local effect. - **Barrier status:** Broken, post-procedure, or eczematous skin is more reactive; patch testing reduces surprise. - **Copper handling disorders:** Wilson disease and severe cholestatic liver disease (bile-flow blockage impairing copper clearance) alter copper handling; systemic copper peptides need specialist oversight. - **Age and comorbidities:** Older adults and people with diabetes use GHK-Cu for wounds, but infection risk and delayed healing still require standard wound care. - **Sex:** No clear sex-specific adverse-event differential is established for GHK-Cu alone. ## Key Interactions & Contraindications - **Strong acids / high-dose L-ascorbic acid (vitamin C) topicals (caution):** Low pH and free copper can oxidize ascorbate and irritate; separate timing (e.g., vitamin C morning, GHK-Cu evening) is commonly used. Consequence: reduced stability or stinging. - **Potent retinoids (tretinoin, adapalene) and chemical peels (caution / monitor):** Additive irritation and barrier stress. Mitigate with alternate-night introduction and moisturization. - **Copper supplements and multivitamins with high copper (monitor if injectable):** Additive copper load with parenteral GHK-Cu is theoretical; track intake if injecting regularly. - **Chelators used for copper overload (e.g., penicillamine, trientine) (caution):** May oppose copper-peptide intent; specialist context only. - **Other regenerative peptides (BPC-157, TB-500) (monitor):** Often combined in clinics; evidence for synergy is anecdotal; additive unknown risks and sourcing quality issues apply. - **Anticoagulants / antiplatelets (warfarin, apixaban, aspirin, clopidogrel) (monitor for injectables):** Injection-site bruising risk, not a specific GHK-Cu pharmacologic interaction. **Populations who should avoid GHK-Cu:** - Wilson disease or known copper toxicosis (systemic use) - Known allergy to GHK-Cu or formulation excipients - Pregnancy and lactation (insufficient safety data; avoid non-essential systemic use) - Active skin infection at intended topical site until controlled - Reliance on untested research-chemical injectables without identity/purity verification ## Risk Mitigation Strategies - **Prefer topical evidence-backed use first:** Cosmetic or post-procedure topical GHK-Cu has clearer human data than systemic injection, reducing gray-market exposure. - **Start low concentration:** Begin with lower-strength serum/cream (e.g., ~0.1%) every other day, then daily if tolerated, to limit local irritation before escalating. - **Separate from strong acids:** Avoid same-time application with low-pH vitamin C or aggressive peels to limit irritation and oxidation. - **Patch test:** Apply to a small forearm area for several days to catch contact sensitivity before face-wide or wound use. - **Third-party tested sourcing:** For injectables or high-potency products, require HPLC (high-performance liquid chromatography) identity, purity, and endotoxin tests to reduce contamination and mislabeling risk. - **Do not combine with copper overload states:** Exclude Wilson disease and review total copper intake if using parenteral forms to limit systemic copper-excess risk. ## Therapeutic Protocol - **Topical cosmetic (best-studied route):** Leave-on serums or creams providing GHK-Cu, often ~0.05–1% complex, once or twice daily to clean dry skin; many trials used twice-daily application for 8–12 weeks. - **Wound-care topical:** Medical gels/dressings (historical products used roughly 0.4–2% ranges in older studies) under clinician wound protocols — not a self-care substitute for infection control and offloading. - **Injectable (experimental / clinic use):** Compounded subcutaneous GHK-Cu is variously described around 1–2 mg daily or several times weekly; no consensus pharmaceutical dose or approved systemic indication for longevity. - **Time of day:** Topical often evening (or split morning/evening if non-irritating); no strict circadian requirement established. - **Half-life and dosing split:** Free peptide half-life is short; topical is local and repeated daily. Injectable regimens are empirical; split dosing is sometimes used without pharmacokinetic (PK) proof of superiority. - **Genetics:** No validated pharmacogenetic dose algorithm (e.g., APOE for lipid/brain risk variants, MTHFR for folate-processing variants) for GHK-Cu. - **Sex and age:** Protocols are not sex-stratified; older users with thinner barriers may need slower topical titration. - **Baseline copper and skin status:** Check copper dysregulation history before systemic use; photograph skin/wounds at baseline for response tracking. - **Competing approaches:** Standard dermatologic care (retinoids, sunscreen, procedures) and GHK-Cu topicals are alternative or complementary photoaging options; comparative superiority is not established in large head-to-head trials. ## Discontinuation & Cycling - **Duration intent:** Topical cosmetic use is often continuous or seasonal; wound use is time-limited to healing. Systemic longevity injection schedules are open-ended and unstandardized. - **Withdrawal:** No classic withdrawal syndrome is described; skin gains may gradually recede after stopping as remodeling signals fade. - **Tapering:** Not required for topical stop. Injectables are typically stopped without formal taper; watch injection sites. - **Cycling:** Some users cycle injectables (e.g., several weeks on/off) to limit cost and unknown chronic exposure; evidence that cycling preserves efficacy is anecdotal. - **Restart:** Topicals can be restarted after barrier recovery if irritation occurred. ## Sourcing and Quality - **Form matters:** Cosmetic leave-on products with disclosed GHK-Cu (copper tripeptide-1) concentration and stable packaging differ sharply from research vials labeled “not for human use.” - **Third-party testing:** For compounded or research peptides, demand certificate of analysis (identity, purity ≥98% where claimed, heavy metals, endotoxin for injectables). - **Color and handling:** Authentic GHK-Cu solutions are often blue-tinted; store cool, protected from light and repeated freeze–thaw; discard if precipitated or discolored unexpectedly. - **Reputable channels:** Established cosmetic brands and licensed compounding pharmacies under clinician oversight outperform anonymous marketplace research chemicals. - **Regulatory note:** Topical GHK-Cu is widely used in cosmetics. Injectable forms lack an FDA-approved longevity indication; in the US, GHK-Cu has been listed among Category 2 bulk substances with significant safety concerns, restricting conventional pharmacy compounding and pushing supply toward research-only channels. ## Practical Considerations - **Time to effect:** Cosmetic skin changes are typically assessed at 4–12 weeks; wound studies measure weeks. Systemic “longevity” subjective effects, if any, lack validated timelines. - **Common pitfalls:** Combining with irritating actives; expecting retinoid-level wrinkle data from weak vehicles; injecting untested vials; confusing elemental copper supplements with GHK-Cu. - **Regulatory status:** Topical cosmetic ingredient in many markets. Injectable longevity use is not FDA-approved; US Category 2 bulk-substance listing restricts compounding, so many products are research-only and quality-variable. - **Cost and access:** Quality topicals are moderately priced; pharmaceutical-grade compounded injectables and clinic programs can be costly and recurring. ## Interaction with Foundational Habits - **Sleep:** No direct sleep disruption is characteristic of topical GHK-Cu. Indirect: better skin comfort post-procedure may aid rest. None known to replace sleep-driven repair. - **Nutrition:** Potentiating: adequate protein and dietary copper support matrix synthesis. Separate high-dose oral copper if using injectables. Antioxidant-rich diet complements anti-inflammatory aims. - **Exercise:** No evidence of blunted hypertrophy. Wound or post-procedure topicals should not be applied under friction equipment until healed. Training supports circulation that may aid local delivery. - **Stress management:** None as a stress therapy: GHK-Cu does not replace stress reduction. Indirect link only via local repair signaling; chronic stress still impairs barrier and wound healing. ## Monitoring Protocol & Defining Success Before starting, review copper-related disease history (including Wilson disease), current topicals, copper-containing supplements, and concurrent procedures. If injectable use is planned, obtain baseline serum copper, ceruloplasmin, complete blood count, and a metabolic panel, and document product identity and purity certificates. Capture standardized skin photographs and, for wounds, area measurements and infection status so later change is comparable. For cosmetics, reassess clinically at 4, 8, and 12 weeks, then every 3–6 months if continued. Injectable protocols warrant labs at 4–12 weeks, then every 6–12 months, plus ongoing product quality checks. Success means photo or measurement improvement without persistent irritation; longevity claims lack validated GHK-Cu-specific biomarker endpoints. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Serum copper | Lab-specific; often ~70–140 µg/dL (confirm local reference) | Detect excess or deficiency if systemic use | Fasting not usually required; interpret with ceruloplasmin | | Ceruloplasmin | Lab reference (often ~20–40 mg/dL) | Copper transport protein; Wilson workup context | Low with Wilson disease; not a GHK-Cu “target” | | CBC | Age/sex-appropriate reference | General safety if injecting | Complete blood count; baseline and if systemic symptoms | | CMP | Lab reference | Liver/kidney context for systemic protocols | Comprehensive metabolic panel; includes ALT/AST (liver enzymes) and creatinine | | hs-CRP | Often <1.0 mg/L functional goal | Nonspecific inflammation context | High-sensitivity C-reactive protein; not GHK-specific; optional | | Wound area / photos | Improving trend vs own baseline | Primary efficacy for skin/wounds | Standardize lighting; weekly early on | - **Qualitative markers:** Skin firmness and texture on touch; makeup “settling”; post-procedure recovery speed; itch/redness burden; hair shedding subjective count if used for scalp. - **Success definition:** Objective photo or profilometry improvement for cosmetics; ≥50% wound area reduction trajectory where relevant; absence of persistent dermatitis or quality red flags. No validated epigenetic-clock or mortality endpoint is established for GHK-Cu. ## Emerging Research - **Phase 2 topical wound RCT:** [Topical GHK-Cu Gel for Acute Skin Wound Healing](https://clinicaltrials.gov/study/NCT07437586) ([NCT07437586](https://clinicaltrials.gov/study/NCT07437586)) — recruiting Phase 2 randomized, double-blind, vehicle-controlled split-wound study (planned n ≈ 60) of re-epithelialization speed in healthy adults. - **Circulating GHK / GHK-Cu modulation:** [X39 patch effects on circulating GHK and GHK-Cu](https://clinicaltrials.gov/study/NCT07706361) ([NCT07706361](https://clinicaltrials.gov/study/NCT07706361)) — not-yet-recruiting study of patch intervention on blood GHK/GHK-Cu levels (planned n ≈ 100). - **Delivery science:** Liposomal and nano-carrier permeation work (e.g., [Ogórek et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39795193/)) may change how effectively topical GHK-Cu reaches living epidermis. - **Organ-beyond-skin models:** Recent animal data on lung fibrosis, silicosis, colitis, and smoke-related muscle dysfunction could strengthen or narrow systemic claims if human translation succeeds — or weaken enthusiasm if null. - **Independent large cosmetic RCTs:** Larger, non-industry primary trials with preregistered endpoints would stress-test effect sizes from small 8–12 week studies and Pickart-linked literature. ## Conclusion GHK-Cu is a small copper-bound peptide whose levels in blood fall with age. Its biology centers on rebuilding the skin’s structural support, speeding wound repair, supporting antioxidant defenses, and shifting many repair-related genes. The strongest human evidence is on the skin surface: small controlled cosmetic trials and older wound-care studies report firmer, smoother skin and faster closure of some ulcers, with generally mild local side effects. Much of the foundational narrative work comes from a research group with commercial copper-peptide interests, a material conflict when weighing that literature. Injectable use for longevity is intriguing but rests on mechanism, animal models, and clinical anecdote rather than large human outcome trials. The dominant practical risks on that path are product quality, contamination, and unknown long-term safety — not proven organ toxicities at ordinary cosmetic skin doses. Interactions are mainly formulation and irritation issues (acids, retinoids), with copper-overload disease as an absolute reason to avoid systemic copper peptides. For health- and longevity-oriented adults already optimizing sleep, nutrition, training, and proven skin fundamentals, GHK-Cu sits as an add-on option with medium support for skin structure and wound contexts, and only speculative support for whole-body “reset” claims. Evidence quality is uneven by route: clearer for leave-on skin products, thin for whole-body longevity dosing. Uncertainty is highest where marketing claims are strongest — gray-market injectables and sweeping age-reversal claims — and lowest where small trials and decades of cosmetic use converge on modest local benefits. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**